1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base and Forecast Years Timeline
1.8. Key benefits for the stakeholders
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Research Process
3. EXECUTIVE SUMMARY
3.1. Key Findings
3.2. Analyst View
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. GLOBAL ANTI-DIABETIC DRUG MARKET BY DIABETES TYPE
5.1. Introduction
5.2. Type 1
5.3. Type 2
6. GLOBAL ANTI-DIABETIC DRUG MARKET BY DRUG TYPE
6.1. Introduction
6.2. Amylinomimetic drug
6.3. Biguanides
6.4. Alpha-glucosidase inhibitors
6.5. Sodium-glucose transporter (SGLT) 2 inhibitors
6.6. Others
7. GLOBAL ANTI-DIABETIC DRUG MARKET BY ROUTE OF ADMINISTRATION
7.1. Introduction
7.2. Oral
7.3. Insulin
8. GLOBAL ANTI-DIABETIC DRUG MARKET BY SALES CHANNEL
8.1. Introduction
8.2. Prescription
8.3. Over-The-Counter (OTC)
9. GLOBAL ANTI-DIABETIC DRUG MARKET BY GEOGRAPHY
9.1. Introduction
9.2. North America
9.2.1. By Diabetes Type
9.2.2. By Drug Type
9.2.3. By Route of Administration
9.2.4. By Sales Channel
9.2.5. By Country
9.2.5.1. USA
9.2.5.2. Canada
9.2.5.3. Mexico
9.3. South America
9.3.1. By Diabetes Type
9.3.2. By Drug Type
9.3.3. By Route of Administration
9.3.4. By Sales Channel
9.3.5. By Country
9.3.5.1. Brazil
9.3.5.2. Argentina
9.3.5.3. Others
9.4. Europe
9.4.1. By Diabetes Type
9.4.2. By Drug Type
9.4.3. By Route of Administration
9.4.4. By Sales Channel
9.4.5. By Country
9.4.5.1. UK
9.4.5.2. Germany
9.4.5.3. France
9.4.5.4. Spain
9.4.5.5. Italy
9.4.5.6. Others
9.5. Middle East and Africa
9.5.1. By Diabetes Type
9.5.2. By Drug Type
9.5.3. By Route of Administration
9.5.4. By Sales Channel
9.5.5. By Country
9.5.5.1. Saudi Arabia
9.5.5.2. Israel
9.5.5.3. UAE
9.5.5.4. Others
9.6. Asia Pacific
9.6.1. By Diabetes Type
9.6.2. By Drug Type
9.6.3. By Route of Administration
9.6.4. By Sales Channel
9.6.5. By Country
9.6.5.1. China
9.6.5.2. Japan
9.6.5.3. India
9.6.5.4. South Korea
9.6.5.5. Taiwan
9.6.5.6. Thailand
9.6.5.7. Indonesia
9.6.5.8. Others
10. COMPETITIVE ENVIRONMENT AND ANALYSIS
10.1. Major Players and Strategy Analysis
10.2. Market Share Analysis
10.3. Mergers, Acquisitions, Agreements, and Collaborations
10.4. Competitive Dashboard
11. COMPANY PROFILES
11.1. AstraZeneca
11.2. Pfizer Inc.
11.3. Merck & Co., Inc.
11.4. Novo Nordisk A/S
11.5. Eli Lilly and Company
11.6. Glenmark Pharmaceuticals Ltd.
11.7. Abbott
11.8. Boehringer Ingelheim International GmbH